Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) is the leading advisory firm to the neuro-musculoskeletal industry with growing experience in other specialties. Founded in 2004, MCRA is headquartered in Washington, DC, with offices in New York, NY, and Manchester, CT, has more than 50 team members, and serves over 400 unique clients globally. The true value of MCRA is the integration of six business value creators for orthopedic & other medical/surgical specialties: regulatory, reimbursement, clinical research, intellectual property, compliance, and quality assurance. MCRA provides “first-in-class” services through its superior knowledge base, global surgeon and physician relationships, and deeply experienced management team. Additionally, MCRA recently started Specialty Healthcare Advisers (SHA), which specializes in healthcare provider consulting. MCRA’s many years of expertise in clinical, reimbursement, regulatory and compliance to provide our clients with a unique 360? integrated perspective. Depending on client needs or goals, MCRA provides clinical trial enrollment strategy and data collection, regulatory strategy, submission and execution, specialty coding & reimbursement recommendations, RAC audit preparedness and defense, Medicare pre-determination assistance, and other services. MCRA’s core clientele are orthopedic spine and biologic medical device companies, private equity firms, CROs, and law firms, and we have an increasing percentage of clientele from other healthcare industries.
Medical Equip
250 - 500 employees
Washington D.c., United States
SFI effectively delivers the right Information Technology solutions and Business Support services using thoughtful analysis, strategic planning and precise execution. Our commitment to excellence in client services, product development and data management means that an attentive team of industry professionals will meet your needs in a straightforward, timely and cost effective manner. SFI is SBA 8(a) and WOSB socio-economic certified. We are also CMMI L3 appraised and ISO 9001 certified.
Tech Services
250 - 500 employees
Washington D.c., United States
Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.
Biotech
50 - 250 employees
Washington D.c., United States